Please ensure Javascript is enabled for purposes of website accessibility

Why Cronos Group Inc. Soared Today

By Keith Speights - Sep 18, 2018 at 12:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for its rivals appears to be lifting this Canadian marijuana stock.

What happened

Shares of Cronos Group Inc. (CRON -5.61%) were up 13.6% as of 11:57 a.m. EDT Tuesday. The Canadian marijuana grower didn't report any news of its own, but it appears its stock received a boost from a positive development for one of its rivals. Tilray (TLRY) announced earlier in the morning that it received approval to supply medical cannabis for a clinical study in the U.S.

In addition, Cronos could also still be enjoying a sustained bump from a report on Monday that Coca-Cola could be looking to make a deal with Aurora Cannabis (ACB -5.12%) to develop cannabis-infused drinks. Aurora released a statement Tuesday morning that said for now "there is no agreement, understanding or arrangement with respect to any partnership with a beverage company." 

Marijuana leaves inside of two plastic capsules.

Image source: Getty Images.

So what

Cronos didn't win approval to ship medical cannabis to the U.S. for a clinical study; Tilray did. Cronos isn't reportedly in talks with Coke; Aurora Cannabis is. So why is Cronos Group stock jumping so much today?

Both of these developments are good for the cannabis industry overall. Tilray's success in obtaining U.S. clearance to supply medical cannabis for a clinical study at the University of California San Diego reminded investors of two things: the tremendous potential for cannabis in treating more medical conditions and the possibility that the U.S. could relax its federal marijuana laws. 

When those things are on investors' minds, it's good for Cronos. Like Tilray, Cronos is keenly interested in expanding the use of medical cannabis. The company's recent deal with Ginkgo Bioworks to produce high-quality cannabinoids underscores that interest. And, of course, Cronos would likely be one of several big winners if the U.S. changes its laws in a way that allowed Canadian marijuana growers to enter the U.S. market.

As for the potential deal between Aurora Cannabis and Coca-Cola, I think Aurora's statement today served as a reminder that nothing is finalized. Could that mean Cronos is still a possible candidate? Maybe, although there's no reason at this point to suspect that's the case. What's important is that if Coke is seeking out a cannabis partner, other major beverage companies will likely follow suit. Cronos would almost certainly be on the short list of big companies looking for a cannabis partner.

Now what

There are two primary things that could serve as nice catalysts for Cronos Group in the months ahead. The Canadian recreational marijuana market opens in October. A great launch for recreational marijuana sales in the country would likely send marijuana stocks higher, including Cronos. The other possible catalyst for Cronos is the potential of landing a deal with a major beverage company -- or perhaps a large tobacco company.

However, marijuana stock valuations are extremely frothy. Cronos Group is no exception. Any bumps in the road could cause this now high-flying stock to fall as quickly as it has risen.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
$3.20 (-5.61%) $0.19
Aurora Cannabis Stock Quote
Aurora Cannabis
$2.78 (-5.12%) $0.15
Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.